Oral Oncology
Volume 36, Issue 1 , Pages 3-7 , January 2000

An overview of the cell cycle arrest protein, p21WAF1

Received 16 June 1999 ,Accepted 22 June 1999.

References 

  1. El-Deiry WS, Tokino T, Velculescu VE, et al.  WAF-1, a potential mediator of p53 tumour suppression. Cell. 1993;75:817–825
  2. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin idependent kinases. Cell. 1993;75:805–816
  3. Xiong Y, Hannon GJ, Zang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinase. Nature. 1993;366:701–704
  4. Noda A, Ning Y, Venable SF, Pereria-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 1994;211:90–98
  5. Jiang H, Fisher PB. Use of a sensitive and efficient subtraction hybridisation protocol for the identification of genes differentially regulated during the induction of differentiated in human melanoma cells. Molec. Cell Different. 1993;1:285–299
  6. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature. 1993;366:707–710
  7. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordeonez JV, Fontana JA. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene. 1994;9:3407–3415
  8. Zeng YX, El Deiry WS. Regulation of p21WAF1/Cip1 expression by p53-independent pathways. Oncogene. 1996;12:1557–1564
  9. Macleod KF, Sherry N, Hannon G, et al.  p53-Dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes and Development. 1995;9:935–944
  10. Kaghad M, Bonnet H, Yang A, et al.  Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–819
  11. Osada M, Ohba M, Kawahara C, et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Medicine. 1998;4:839–843
  12. White E. p53, guardian of Rb. Nature. 1994;372:21
  13. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of cyclin-dependent kinase inhibitor p21. Oncogene. 1994;9:2261–2268
  14. Steinman RA, Hoffman B, Iro A, Guillouf C, Lieberman DA, El-Houseini ME. Induction of p21(WAF-1/CIP1) during differentiation. Oncogene. 1994;9:3389–3396
  15. Gorz C, Montenarh M. p53 and its implications in apoptosis. Int. J. Oncol. 1995;6:1129–1135
  16. Suardet L, Li CA, Little JB. Radio-induced modulation of transforming growth factor beta 1 sensitivity in a p53 wild-type human colorectal-cancer cell line. Int. J. Cancer. 1996;68:126–131
  17. Gorospe M, Wang X, Holbrook NJ. p53-dependent elevation of p21WAF1 expression by UV light is mediated through mRNA stabilization and involves a vanadate-sensitive regulatory system. Molec. Cell Biol. 1998;18:1400–1407
  18. Brugarolas J, Chandrasekaran C, Gordon JI, et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 1995;377:552–557
  19. LaBaer J, Garrett MG, Stevenson LF, et al.  New functional activities for the p21 family of CDK inhibitors. Genes and Development. 1997;27:847–862
  20. Shivji MKK, Ferrari E, Ball K, et al.  Resistance of human nucleotide excision repair synthesis in vitro to p21Cdn1. Oncogene. 1998;17:2827–2838
  21. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature. 1994;369:574–576
  22. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes and Development. 1994;8:1750–1758
  23. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Molec. Biol. Cell. 1993;4:897–906
  24. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/Cip1 by a p53- independent pathway. Cancer Res. 1994;54:3391–3395
  25. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol. 1995;47:884–886
  26. Elbendary A, Berchuck A, Davis P, et al.  Transforming growth-factor-beta-1 can induce Cip1/Waf 1 expression independent of the p53 pathway in ovarian-cancer cell. Cell Growth and Differentiation. 1994;5:1307–1310
  27. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor induces the cyclin-dependent kinase inhibitor p21 thought a p53-independent mechanism. Proc. Natl. Acad. Sci. USA. 1995;92:5545–5549
  28. Yoshida K, Murohashi I, Bessho M, Hirashima K. p53-independent induction of p21 (WAF1/CIP1) during differentiation of HL-60 cells by tumor necrosis factor alpha. Experimental Hematology. 1997;25:166
  29. Yoshida K, Murohashi I, Hirashima K. p53-independent induction of p21 (WAF1/CIP1) during differentiation of HL-60 cells by tumor necrosis factor alpha. Int. J. Hematology. 1996;65:41–48
  30. Arany I, Brysk MM, Calhoun KH, Tyring SK. Differentiation and IFN gamma regulate WAF1/CIP1 transcription in p53-independent and p53-dependent pathways in epithelial cells. In Vivo. 1996;10:119–123
  31. Zhang W, Grasso L, Mcclain CD, et al.  p53-independent induction of WAF1/C1P1 in human leukemia-cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 1995;55:668–674
  32. James SY, Mackay AG, Colston KW. Effects of 1,25-dihydoxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Molec. Biol. 1996;58:395–401
  33. Greenhalgh DA, Wang XJ, Donehower LA, Roop DR. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-ras Ha, v-fos, or human transforming growth factor alpha. Cancer Res. 1996;56:4413–4423
  34. Halevy O, Novitch BG, Spicer DR, et al.  Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21WAF1/Cip1 by MyoD. Science. 1995;267:1018–1021
  35. Billon N, vanGrunsven LA, Rudkin BB. The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells. Oncogene. 1996;267:1018–1021
  36. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. Association between the p21 codon 31 Al (Arg) allele and lung cancer. Hum. Hered. 1996;46:221–225
  37. Kawasaki T, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/Cip1 and/or p53 gene alterations. Int J Cancer 1996;68:501–505.
  38. Bhatia K, Fan S, Spangler G, et al.  A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res. 1995;55:1431–1435
  39. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21Cip1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995;82:675–684
  40. McDonald ER, Wu GS, Waldman T, El Deiry WS. Repair defect in p21WAF1/Cip1 −/− human cancer cells. Cancer Res. 1996;56:2250–2255
  41. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differentiational effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature. 1994;371:534–537
  42. Shivji MKK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision repair. Curr. Biol. 1994;4:1062–1068
  43. Warbrick E, Lane DP, Glover DM, Cox LS. Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a possible mechanism for regulation of DNA replication. Oncogene. 1997;14:2313–2321
  44. Podust VN, Podust LM, Goubin F, et al.  Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry. 1995;34:8869–8875
  45. Chen JJ, Chen S, Saha P, Dutta A. p21(Cip1/Waf1) disrupts the recruitment of human Fenl by proliferating-cell nuclear antigen into the DNA replication complex. Proc. Natl. Acad. Sci. USA. 1996;93:11597–11602
  46. Savio M, Stivala LA, Scovassi AI et al. p21WAF1/Cip1 protein associates with the detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites. Oncogene 1996;13:1591–1598.
  47. Jiang H, Lin J, Su Z, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 1994;9:3397–3406
  48. Van Oijen MGCT, Tilanus MGJ, Medema RH, Slootweg PJ. Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J. Oral Pathol. Med. 1998;27:367–375
  49. Warnakulasuriya KAAS, Tavassoli M, Johnson NW. Relationship of p53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J. Oral Pathol. Med. 1998;27:376–381
  50. Hogno A, Lindskog S, Lindholm J, Kuylenstierna R, Auer G, Munck-Wikland E. Preneoplastic oral lesions: the clinical value of image cytometry DNA analysis, p53 and p21/WAF1 expression. Anticancer Res. 1998;18:3645–3650
  51. Kudo Y, Takata T, Ogawa I, Sato S, Nikai H. Expression of p53 and p21(CIP1/WAF1) proteins in oral epithelial dysplasia and squamous cell carcinomas. Oncology Reports. 1999;6:539–545
  52. Schoelch ML, Regezi JA, Dekker NP, et al.  Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncology. 1999;35:333–342
  53. Tatemoto Y, Osaki T, Yoneda K, Yamamoto T, Ueta E, Kimura T. Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. Pathology Res. Practice. 1998;194:821–830
  54. Agarwal S, Mathur M, Shukla NK, Ralhan R. Expression of cyclin dependent kinase inhibitor p21(waf1/cip1) in premalignant and malignant oral lesions: relationship with p53 status. Oral Oncol. 1998;34:353–360
  55. Yoneda K, Yamamoto T, Osaki T. p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation. Oral Oncology. 1998;34:529–537
  56. Ng IOL, Lam KY, Ng M, Regezi JA. Expression of p21/waf1 in oral squamous cell carcinomas—correlation with p53 and mdm2 and cellular proliferation index. Oral Oncology. 1999;35:63–69
  57. El-Deiry WS, Harper JW, Oconnor PM, et al.  WAF-1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169–1174
  58. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the abscence of transcriptional activation of p53-target genes. Nature. 1994;370:220–223
  59. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking WAF1/Cip1. Nature. 1996;381:713–716
  60. Wouters BG, Giaccia AJ, Denko NC, Brown JM. Loss of p21WAF1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 1997;54:4703–4706
  61. Ruan S, Okcu MF, Ren JP, et al.  Overexpressed WAF-1/CIP1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res. 1998;58:1538–1543
  62. Levkau B, Koyama H, Raines EW, et al.  Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. Mol. Cell. 1998;1:553–563
  63. Zhang Y, Fujita N, Tsuruo T. Caspase-mediated cleavage of p21WAF1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene. 1999;18:1131–1138
  64. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumour-suppressor genes. Oncogene. 1992;7:927–933
  65. Somers KD, Merrick MA, Lopez ME, Incognito LA, Schechter GL, Casey G. Frequent. p53 mutations in head and neck cancer. Cancer Res. 1992;52:5997–6000
  66. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53
  67. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by p21WAF1. Cancer Res. 1995;55:4536–4539
  68. Bae I, Fan S, Bhatia K, Kohn KW, Fornace AJ, O'Connor PM. Relationships between g1 arrest and stability of the p53 and p21cip1/waf1 proteins following gamma-irradiation of human lymphoma cells. Cancer Res. 1995;55:2387–2393
  69. Eastham JA, Hall SJ, Sehgal I, et al.  In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 1995;55:5151–5155
  70. Cardinali M, Jakus J, Shah S, Ensley JF, Robbins KC, Yeudall WA. p21(WAF-1/CIP1) retards the growth of human squamous cell carcinoma in vivo. Oral Oncology. 1998;34:211–218
  71. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol. 1995;147:884–888
  72. Marchetti A, Doglioni C, Barbareschi M, et al.  p21 RNA and protein expression in non-small cell lung carcinoma: evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 1996;12:1319–1324
  73. Barboule N, Mazars P, Baldin V, et al.  Expression of p21WAF1/cip1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer. 1995;63:611–615
  74. Elbendary AA, Cirisano FD, Evans AC, et al.  Relationship between p21 expression and mutaion of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer Res. 1996;2:1571–1575
  75. Yasui W, Akama Y, Kuniyasu H, et al.  Expression of cyclin-dependent kinase inhibitor p21/WAF1/CIP1, in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J. Pathol. 1996;180:122–128
  76. Nadal A, Jares P, Cazorla M, et al.  p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J. Pathol. 1997;183:156–163
  77. Bukholm K, Nesland JM, Karesen R, Jacobsen U, Borresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J. Pathol. 1997;181:140–145
  78. Rey MJ, Fernandez PL, Jares P, et al.  p21WAF1/Cip1 is associated with Cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J. Pathol. 1998;184:265–271
  79. El-Deiry WS, Tokino T, Waldman T, et al.  Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995;55:2910–2919
  80. Yook JI, Kim J. Expression of p21 WAF-1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncology. 1998;34:198–203
  81. Ito K, Sasano H, Matsunaga G, et al.  Correlations between p21 expression and clinicopathological findings p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J. Pathol. 1997;183:318–324
  82. Qin LF, Ng IOL, Fan ST, Ng M. p21, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int. J. Cancer. 1998;79:424–428
  83. Tron VA, Tang L, Yong WP, et al.  Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. Am. J. Pathol. 1996;149:1139–1146
  84. Erber R, Klein W, Andl T, et al.  Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int. J. Cancer. 1997;74:383–389
  85. Viale G, Pellegrini C, Mazzarol G, et al.  p21WAF1/Cip1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. J. Pathol. 1999;187:302–307
  86. Lukas J, Groshen S, Saffari B, et al.  WAF1/Cip 1 gene polymorphism and expression in carcinomas of the breast, ovary and endometrium. Am. J. Pathol. 1997;150:167–175
  87. Sato M, Harada K, Yoshida H, et al.  Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis. 1997;2:227–238

PII: S1368-8375(99)00049-4

Oral Oncology
Volume 36, Issue 1 , Pages 3-7 , January 2000

Article Tools